SRZN — Surrozen, Inc./DE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1824893 ·
Last close
$29.98
Market Cap
$571.47M
52W High
$37.83
52W Low
$12.75
ADV30
385,977
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 5,000,000 | — | -10,370,000 | 50,177,000 | 115,606,000 | 102,039,000 | 334,271,000 |
| Mar 2026 | 5,000,000 | — | -10,456,000 | -127,505,000 | 120,709,000 | 106,910,000 | 398,856,000 |
| Dec 2025 | 528,000 | — | -12,639,000 | -183,159,000 | 98,726,000 | 89,245,000 | 286,488,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,550,000
Investing CF
$-225,000
Financing CF
$49,740,000
CapEx
$-225,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-31.44
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-734,337,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-51,107,000
Pretax Income TTM
$-390,211,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,528,000
EBITDA
$-50,895,000
Free Cash Flow
$-14,758,875
Enterprise Value
$508,023,136
Total Cash
$100,353,000
Total Debt
$5,837,000
Shares Out
19,061,662
Trailing EPS
$-41.94
Book Value
$-27.90
ROE
—
ROA
-31.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,477,000 | -42,092,000 | -242,026,000 | 98,726,000 | 286,488,000 | -187,762,000 | -30,244,000 |
| Dec 2024 | 10,655,000 | -25,539,000 | -63,564,000 | 48,467,000 | 69,847,000 | -21,380,000 | -17,628,000 |
| Dec 2023 | 0 | -43,028,000 | -43,042,000 | 46,080,000 | 8,145,000 | 37,935,000 | -40,363,000 |
| Dec 2022 | 12,500,000 | -44,339,000 | -36,004,000 | 89,435,000 | 13,434,000 | 76,001,000 | -44,145,000 |
TTM Snapshot
Revenues TTM
$11,511,000
NetIncome TTM
$-332,130,000
OpCashFlow TTM
—
Assets (Latest)
$115,606,000
Forward EPS
$-4.71
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $31.74 · call volume: 87 · put volume: 5Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SANA | Sana Biotechnology, Inc. | $563.31M | $1.88 | — |
| CGEM | Cullinan Therapeutics, Inc. | $602.14M | $9.27 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $608.33M | $10.79 | — |
| VALN | Valneva SE | $527.69M | $5.57 | — |
| ETRA | Electra Therapeutics, Inc. | $524.10M | $8.35 | — |
News headlines (Yahoo Finance, 1h cache)
Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
2026-11-13 13:00 · Yahoo
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 21:05 · Yahoo
Surrozen to Present at Upcoming Healthcare Investor Conference
2026-11-06 21:40 · Yahoo
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
2026-10-20 20:59 · Yahoo
Top Biotech Stock: Guggenheim Names Surrozen as Best Pick
2026-10-15 18:22 · Yahoo
Surrozen secures FDA clearance for SZN-8141 clinical trial
2026-10-05 10:51 · Yahoo
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
2026-10-02 12:00 · Yahoo
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
2026-09-08 12:30 · Yahoo
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 20:05 · Yahoo
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
2026-07-22 20:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.